|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide LAR has modest in vivo efficacy and the combination of everolimus and pasireotide LAR achieve greater tumor growth inhibition than each agent alone in TPC-1 xenograft model of thyroid cancer (p = 0.048).
|
30807575 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic (8505C, CAL62, SW1736) and papillary (TPC-1) thyroid cancer cell lines were used to dissect the role of miR-650 on malignant hallmarks of transformation.
|
30927143 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.
|
30127885 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the biological role of LRP4 in the thyroid cancer in the present study was investigated using the PTC cell lines TPC1, BCPAP and KTC-1.
|
29885843 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our purpose was to study the combined effect of HDAC inhibitors (HDACi) and ionizing irradiation in thyroid cancer cell lines (Nthy-ori 3-1, WRO, TPC-1 and 8505c).
|
30125607 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the activities of hydroxytyrosol against papillary (TPC-1, FB-2) and follicular (WRO) thyroid cancer cell lines.
|
27592355 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, a knockdown of galectin-1 in papillary (TPC-1) and anaplastic (8505C) thyroid cancer cell lines was achieved by lentiviral transduction for in vitro experiments.
|
28677745 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of epithelial to mesenchymal transition (EMT) by transforming growth factor (TGF)-beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors.
|
27696303 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BAK1 gene expression showed down-regulation in thyroid tumours (follicular and papillary tumours) and in TPC-1 and CAL-62 cell lines.
|
25617717 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that a TRAIL-R2 agonist antibody, lexatumumab, induces apoptosis effectively in some thyroid cancer cell lines (HTh-7, TPC-1 and BCPAP), while more aggressive anaplastic cell lines (8505c and SW1736) show resistance.
|
24603332 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 3 thyroid cancer cell lines (TPC1 from a papillary thyroid cancer, FTC133 from a follicular thyroid cancer, XTC1 from a Hürthle cell carcinoma), small interfering RNA knockdown of RTN4IP1 was used to determine its role in regulating the hallmarks of malignant cell phenotype (cellular proliferation, migration, apoptosis, invasion, tumor spheroid formation, anchorage independent growth).
|
23393170 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using 76 papillary thyroid cancer(PTC) tissues and three thyroid cancer cell lines (TPC1, WRO82-1 and XTC), the expression of three genes and DNA methylation were determined by reverse transcription-PCR and methylation-specific PCR.
|
24222120 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three anaplastic (Hth74, C643, Kat4), one follicular (FTC133), and one papillary (TPC1) TC cell lines were used.
|
22006286 |
2012 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E).
|
21355020 |
2011 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib.
|
19878585 |
2009 |